FDA advisers to weigh composition of COVID vaccines for 2026-2027

By Christy Santhosh May 28 (Reuters) - The U.S. FDA's advisory panel will vote on Thursday on whether COVID-19 vaccines for ...
MedPage Today

FDA Panel Backs New COVID Vaccines Aimed at Dominant Strain

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) also discussed the need to target the long-simmering ...
Medscape

FDA Advisors Favor Dominant US Strain, XFG, for Next COVID Vaccine

Experts skipped the cicada variant BA.3.2 and last year’s LP.8.1 vaccine strain and recommended monovalent XFG option.

FDA panel recommends updating covid shots to target XFG strain

A Food and Drug Administration advisory panel on Thursday recommended updating this fall’s Covid shots to target the XFG ...

US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant

May 26 (Reuters) - Advisers to the U.S. Food and Drug Administration will discuss whether COVID-19 vaccines should be updated to target the latest circulating XFG subvariant for the 2026-27 ...
MedPage Today on MSN

FDA's Vaccine Panel to Weigh XFG Variant for New COVID Shots

But advisors will take a hard look at "Cicada" variant as well ...
Pharm Exec

FDA’s Advisory Panel Votes in Favor of Updating Covid-19 Vaccine Shots to Target XFG Variant

VRBPAC is evaluating an XFG-targeted composition for 2026–2027 vaccines, based on CDC variant prevalence estimates that are more than a month old. FDA briefing materials emphasize eroding sequencing ...
U.S. News & World Report

Sanofi Sees Near-Term Weakness in US Vaccines Sales Due to Antivax Rhetoric

SAN FRANCISCO, Jan 14 (Reuters) - Sanofi Chief Executive Paul Hudson ‌said on Wednesday the company is likely ‌to see some weakness in U.S. vaccine demand this year due to scepticism in immunizations ...

Moderna Vaccine

Read Moderna Vaccine latest news on The Economic Times. Moderna Vaccine updates, Moderna Vaccine videos & more.